249 related articles for article (PubMed ID: 25965947)
21. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
Morgado M; Carson DD
J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
Morgado M; Sutton MN; Simmons M; Warren CR; Lu Z; Constantinou PE; Liu J; Francis LL; Conlan RS; Bast RC; Carson DD
Oncotarget; 2016 Mar; 7(12):14871-84. PubMed ID: 26918940
[TBL] [Abstract][Full Text] [Related]
23. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
[TBL] [Abstract][Full Text] [Related]
24. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
[TBL] [Abstract][Full Text] [Related]
25. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
[TBL] [Abstract][Full Text] [Related]
26. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.
Das S; Majhi PD; Al-Mugotir MH; Rachagani S; Sorgen P; Batra SK
Sci Rep; 2015 Jun; 5():9759. PubMed ID: 26044153
[TBL] [Abstract][Full Text] [Related]
27. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
28. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
29. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16.
Bouanene H; Miled A
Dis Markers; 2010; 28(6):385-94. PubMed ID: 20683153
[TBL] [Abstract][Full Text] [Related]
30. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
Williams KA; Terry KL; Tworoger SS; Vitonis AF; Titus LJ; Cramer DW
PLoS One; 2014; 9(2):e88334. PubMed ID: 24551091
[TBL] [Abstract][Full Text] [Related]
32. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis.
Liu Q; Cheng Z; Luo L; Yang Y; Zhang Z; Ma H; Chen T; Huang X; Lin SY; Jin M; Li Q; Li X
Oncotarget; 2016 Jun; 7(24):36800-36813. PubMed ID: 27167110
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract][Full Text] [Related]
34. [MUC16: The Novel Target for Tumor Therapy].
Gao R; Lou N; Han X; Shi Y
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
[TBL] [Abstract][Full Text] [Related]
35. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
36. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
Fan K; Yang C; Fan Z; Huang Q; Zhang Y; Cheng H; Jin K; Lu Y; Wang Z; Luo G; Yu X; Liu C
Cancer Lett; 2018 Apr; 418():167-175. PubMed ID: 29337110
[TBL] [Abstract][Full Text] [Related]
37. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
38. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.
Wang CW; Weaver SD; Boonpattrawong N; Schuster-Little N; Patankar M; Whelan RJ
Cancer Res Commun; 2024 Jan; 4(1):253-263. PubMed ID: 38197671
[TBL] [Abstract][Full Text] [Related]
39. CA125/MUC16 is dispensable for mouse development and reproduction.
Cheon DJ; Wang Y; Deng JM; Lu Z; Xiao L; Chen CM; Bast RC; Behringer RR
PLoS One; 2009; 4(3):e4675. PubMed ID: 19262696
[TBL] [Abstract][Full Text] [Related]
40. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Shukla SK; Gunda V; Abrego J; Haridas D; Mishra A; Souchek J; Chaika NV; Yu F; Sasson AR; Lazenby AJ; Batra SK; Singh PK
Oncotarget; 2015 Aug; 6(22):19118-31. PubMed ID: 26046375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
